

Kasper Rossing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12082968/publications.pdf>

Version: 2024-02-01

56
papers

4,389
citations

172386
29
h-index

168321
53
g-index

56
all docs

56
docs citations

56
times ranked

3571
citing authors

#	ARTICLE	IF	CITATIONS
1	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	2.5	434
2	Clinical proteomics: A need to define the field and to begin to set adequate standards. <i>Proteomics - Clinical Applications</i> , 2007, 1, 148-156.	0.8	274
3	Progression of nephropathy in type 2 diabetic patients. <i>Kidney International</i> , 2004, 66, 1596-1605.	2.6	270
4	Urinary Proteomics in Diabetes and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1283-1290.	3.0	267
5	Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study. <i>Diabetes Care</i> , 2005, 28, 2106-2112.	4.3	266
6	Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial. <i>Diabetes Care</i> , 2003, 26, 2268-2274.	4.3	222
7	Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. <i>Journal of Proteome Research</i> , 2009, 8, 268-281.	1.8	221
8	Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. <i>Kidney International</i> , 2003, 63, 1874-1880.	2.6	205
9	Beneficial impact of spironolactone in diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 2829-2836.	2.6	201
10	Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study. <i>Diabetes Care</i> , 2002, 25, 95-100.	4.3	200
11	Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. <i>Kidney International</i> , 2005, 68, 1190-1198.	2.6	196
12	CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. <i>Proteomics - Clinical Applications</i> , 2008, 2, 964-973.	0.8	178
13	Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. <i>Kidney International</i> , 2005, 68, 193-205.	2.6	126
14	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. <i>PLoS ONE</i> , 2010, 5, e13421.	1.1	117
15	Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1019-1024.	0.4	112
16	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. <i>Kidney International</i> , 1998, 53, 1002-1006.	2.6	91
17	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. <i>Kidney International</i> , 1999, 56, S101-S105.	2.6	80
18	Evolving strategies for renoprotection: diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 515-522.	1.0	76

#	ARTICLE	IF	CITATIONS
19	Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. <i>European Journal of Heart Failure</i> , 2014, 16, 403-408.	2.9	74
20	Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study. <i>Diabetes Care</i> , 2003, 26, 150-155.	4.3	73
21	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. <i>Diabetes Care</i> , 2014, 37, 1660-1667.	4.3	68
22	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008, 2, 997-1007.	0.8	64
23	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. <i>Kidney International</i> , 1996, 49, 1778-1782.	2.6	63
24	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 767-777.	1.2	61
25	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. <i>Seminars in Nephrology</i> , 2004, 24, 147-157.	0.6	57
26	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. <i>PLoS ONE</i> , 2010, 5, e13051.	1.1	51
27	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. <i>PLoS ONE</i> , 2016, 11, e0157167.	1.1	42
28	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
29	Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. <i>International Journal of Cardiology</i> , 2013, 170, 202-207.	0.8	32
30	Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure: A substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study. <i>Diabetes Care</i> , 2003, 26, 569-574.	4.3	30
31	Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Nephrology and Hypertension, 2004, 13, 319-324.	1.0	23
32	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. <i>Amino Acids</i> , 2012, 42, 1627-1639.	1.2	22
33	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 161-166.	1.0	21
34	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 137-142.	0.6	18
35	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. <i>Journal of Translational Medicine</i> , 2016, 14, 203.	1.8	17
36	Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome. <i>ESC Heart Failure</i> , 2019, 6, 379-387.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Computed Tomographyâ€“Estimated Right Ventricular Function and Exercise Capacity in Patients with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 8-16.	0.9	12
38	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2021, 14, e008662.	1.6	10
39	Intravascular ultrasoundâ€“guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14124.	0.8	7
40	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. <i>International Journal of Cardiology</i> , 2014, 177, 942-948.	0.8	6
41	Long-term prognosis following hospitalization for acute myocarditis â€“ a matched nationwide cohort study. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 264-269.	0.4	6
42	Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy. <i>Oxford Medical Case Reports</i> , 2021, 2021, omaa150.	0.2	6
43	Outcomes and hospital admissions during long-term support with a HeartMate II. <i>Scandinavian Cardiovascular Journal</i> , 2015, 49, 367-75.	0.4	6
44	Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. <i>ESC Heart Failure</i> , 2017, 4, 554-562.	1.4	4
45	Relationship between invasive hemodynamics and liver function in advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 235-246.	0.4	4
46	Clinical presentation and outcomes in women and men with advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 361-368.	0.4	4
47	Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2555-2567.	1.4	4
48	Oxygen Uptake During Activities of Daily Life in Patients Treated With a Left Ventricular Assist Device. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 982-990.	0.3	4
49	Copeptin levels and invasive hemodynamics in patients with advanced heart failure. <i>Biomarkers in Medicine</i> , 2018, 12, 861-870.	0.6	3
50	Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. <i>Cardiology</i> , 2020, 145, 769-778.	0.6	3
51	Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	3
52	Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?. <i>European Journal of Heart Failure</i> , 2018, 20, 175-177.	2.9	1
53	Pulmonary artery pressure as a method for assessing hydration status in an anuric hemodialysis patient â€“ a case report. <i>BMC Nephrology</i> , 2020, 21, 266.	0.8	1
54	Three decades of heart transplantation: experience and long-term outcome. <i>Scandinavian Cardiovascular Journal</i> , 2022, 56, 65-72.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results. Open Forum Infectious Diseases, 2017, 4, S703-S703.	0.4	0
56	Reassessment of Gene-Elusive Familial Dilated Cardiomyopathy Leading to the Discovery of a Homozygous AARS2 Variantâ€”The Importance of Regular Reassessment of Genetic Findings. Neurology International, 2021, 11, 122-128.	0.2	0